Skip to main content
. 2022 Jun 24;28:100944. doi: 10.1016/j.conctc.2022.100944

Table 3.

Network meta-analysis results of the risk ratio of adverse events in patients with the following interventions: ORS=Oral semaglutide, SUS=Subcutaneous semaglutide, GLP = GLP-1 RA comparator, and PLC=Placebo.

Network comparison, adverse events
SUSrowhead
0.12 (−0.30, 0.54) ORS
0.20 (−0.13, 0.53) 0.08 (−0.32, 0.48) GLP
0.15 (−0.20, 0.50) 0.03 (−0.29, 0.36) −0.05 (−0.42, 0.33) PLC